Pharmaceutical composition for treating or alleviating autoimmune-related diseases and method for treating or alleviating autoimmune-related diseases

Abstract

A pharmaceutical composition for treating or alleviating autoimmune-related diseases is provided, including an extract of Amomum tsao - ko as an active ingredient and a pharmaceutically acceptable carrier, in which the extract comprises Vanillin, Tsaokoin, or the combination thereof.

What is claimed is: 
     
         1 . A pharmaceutical composition for treating or alleviating autoimmune-related diseases, comprising:
 an extract of  Amomum tsao - ko  as an effective ingredient and a pharmaceutically acceptable carrier or salt.   
     
     
         2 . The pharmaceutical composition as claimed in  claim 1 , wherein the extract of  Amomum tsao - ko  is extracted from a root, a stem, a leaf, a flower, a fruit, a seed, or a combination thereof. 
     
     
         3 . The pharmaceutical composition as claimed in  claim 1 , wherein the extract of  Amomum tsao - ko  is obtained from performing an extraction with an organic solvent. 
     
     
         4 . The pharmaceutical composition as claimed in  claim 3 , wherein the organic solvent comprises alcohol, ester, alkane, haloalkane solvent or a combination thereof. 
     
     
         5 . The pharmaceutical composition as claimed in  claim 4 , wherein the organic solvent is 50-95% alcohol solvent. 
     
     
         6 . The pharmaceutical composition as claimed in  claim 3 , wherein a volume of the organic solvent is 3-10 times the weight of  Amomum tsao - ko.    
     
     
         7 . The pharmaceutical composition as claimed in  claim 3 , wherein the extraction of the extract of  Amomum tsao - ko  is performed with an extraction temperature of 10 to 35° C. and an extraction time of 3 to 10 days. 
     
     
         8 . The pharmaceutical composition as claimed in  claim 3 , wherein the extraction of the extract of  Amomum tsao - ko  is further performed with a shaking mode. 
     
     
         9 . The pharmaceutical composition as claimed in  claim 8 , wherein the extraction of the extract of  Amomum tsao - ko  further comprises a distillation step. 
     
     
         10 . The pharmaceutical composition as claimed in  claim 9 , wherein the extraction of the extract of  Amomum tsao - ko  further comprises a heating reflux step with a low polarity solvent. 
     
     
         11 . The pharmaceutical composition as claimed in  claim 1 , wherein the pharmaceutical composition has the effect on inhibiting cytokine secretion, wherein the cytokine includes IL-17, TNF-α, and a combination thereof. 
     
     
         12 . The pharmaceutical composition as claimed in  claim 1 , wherein the autoimmune-related diseases is selected from the group consisting of Multiple Sclerosis (MS), neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), demyelination-related neuritis, Ankylosing spondylitis, Psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease, Juvenile idiopathic arthritis (JIA), and Ulcerative Colitis (UC). 
     
     
         13 . The pharmaceutical composition as claimed in  claim 1 , wherein the autoimmune-related diseases is Multiple Sclerosis (MS). 
     
     
         14 . The pharmaceutical composition as claimed in  claim 1 , wherein the pharmaceutical composition is administered orally, non-orally, parenterally by an inhalation spray, or via an implanted reservoir. 
     
     
         15 . A method of treating or alleviating autoimmune-related diseases, comprising:
 administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises an extract of  Amomum tsao - ko  as an effective ingredient and a pharmaceutically acceptable carrier or salt.   
     
     
         16 . A pharmaceutical composition for treating or alleviating autoimmune-related diseases, comprising:
 a compound as an effective ingredient and a pharmaceutically acceptable carrier or salt, wherein the compound is vanillin, tsaokoin, or a combination thereof.   
     
     
         17 . The pharmaceutical composition as claimed in  claim 16 , wherein the pharmaceutical composition has the effect on inhibiting cytokine secretion, wherein the cytokine includes IL-17, TNF-α, and a combination thereof. 
     
     
         18 . The pharmaceutical composition as claimed in  claim 16 , wherein the autoimmune-related diseases is selected from the group consisting of Multiple Sclerosis (MS), neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), demyelination-related neuritis, Ankylosing spondylitis, Psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease, Juvenile idiopathic arthritis (JIA), and Ulcerative Colitis (UC). 
     
     
         19 . The pharmaceutical composition as claimed in  claim 16 , wherein the autoimmune-related diseases is Multiple Sclerosis (MS). 
     
     
         20 . The pharmaceutical composition as claimed in  claim 16 , wherein the pharmaceutical composition is administered orally, non-orally, parenterally by an inhalation spray, or via an implanted reservoir. 
     
     
         21 . A method of treating or alleviating autoimmune-related diseases, comprising:
 administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a compound as an effective ingredient and a pharmaceutically acceptable carrier or salt, wherein the compound is vanillin, tsaokoin, or a combination thereof.